Boston Scientific Corporation (BSX) |
|
|
|
Boston Scientific Income Statement Quarterly
BSX
Select the Financial Report: |
Period: |
Fiscal Year: |
|
|
|
INCOME STATEMENT (Quarterly GAAP In millions $) |
(Dec 31 2019) IV. Quarter |
(Sep 30 2019) III. Quarter |
(Jun 30 2019) II. Quarter |
(Dec 31 2018) IV. Quarter |
(Sep 30 2018) III. Quarter |
Revenue From Contract With Customer Excluding Assessed Tax |
|
2,707.00 |
2,631.00 |
|
- |
Revenue From Contract With Customer Excluding Assessed Tax |
|
- |
- |
|
2,393.00 |
Other Revenue |
|
- |
- |
|
-1.00 |
Total Revenue |
5,398.00 |
2,707.00 |
2,631.00 |
2,563.00 |
2,392.00 |
Cost of Goods and Services Sold |
1,581.00 |
777.00 |
758.00 |
730.00 |
672.00 |
Gross
Profit |
2,054.00 |
1,930.00 |
1,873.00 |
1,833.00 |
1,720.00 |
Selling, Administration, Marketing |
1,092.00 |
1,012.00 |
968.00 |
953.00 |
870.00 |
Depriciation & Amortization |
200.00 |
178.00 |
161.00 |
163.00 |
148.00 |
Research and Development Expense (Excluding Acquired in Process Cost) |
308.00 |
306.00 |
280.00 |
288.00 |
289.00 |
Restructuring, Accretion & impairment charges |
29.00 |
3.00 |
38.00 |
15.00 |
3.00 |
Other operatinig exp. /-income |
1,791.00 |
- |
- |
1.00 |
- |
Litigation Settlement, Expense |
223.00 |
25.00 |
15.00 |
85.00 |
18.00 |
Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability |
- |
8.00 |
10.00 |
- |
-13.00 |
Fees and Commission |
17.00 |
15.00 |
17.00 |
18.00 |
17.00 |
Total operating costs including COS |
5,188.00 |
2,324.00 |
2,247.00 |
2,244.00 |
2,004.00 |
Operating income/-loss
|
210.00 |
383.00 |
384.00 |
319.00 |
388.00 |
Other Deductions / - Income |
Interest expense |
180.00 |
95.00 |
89.00 |
65.00 |
58.00 |
Interest income |
- |
- |
- |
- |
- |
Net interest expense/-income |
180.00 |
95.00 |
89.00 |
65.00 |
58.00 |
Loss/ -Gain on Investment |
- |
- |
- |
- |
- |
Income from affiliates |
- |
- |
- |
- |
- |
Unrealized Loss/ -Income |
- |
- |
- |
- |
- |
Financing Loss/ -Income |
- |
- |
- |
- |
- |
Other loss/ -income |
36.00 |
197.00 |
150.00 |
-42.00 |
-126.00 |
Total costs & expenses |
5,404.00 |
2,616.00 |
2,486.00 |
2,267.00 |
1,936.00 |
Income /-loss before income taxes |
-6.00 |
91.00 |
145.00 |
296.00 |
456.00 |
Income taxes expenses/-benefit |
-4,002.00 |
-35.00 |
-9.00 |
-90.00 |
24.00 |
Income after income taxes |
3,996.00 |
126.00 |
154.00 |
386.00 |
432.00 |
Net income/-loss
of other equity |
- |
- |
- |
- |
- |
Income/-loss
from cont. Ops. |
3,996.00 |
126.00 |
154.00 |
386.00 |
432.00 |
Accounting change |
- |
- |
- |
- |
- |
Discontinued operations |
- |
- |
- |
- |
- |
Extraordinary items |
- |
- |
- |
- |
- |
Net Income/-loss |
3,996.00 |
126.00 |
154.00 |
386.00 |
432.00 |
Noncontrolling interests |
- |
- |
- |
- |
- |
Prefered dividends |
- |
- |
- |
- |
- |
Other |
- |
- |
- |
- |
- |
Income/-loss to shareholder |
3,996.00 |
126.00 |
154.00 |
386.00 |
432.00 |
EBIT |
174.00 |
186.00 |
234.00 |
361.00 |
514.00 |
EBITD |
1,185.00 |
186.00 |
234.00 |
1,255.00 |
514.00 |
EBITDA |
1,185.00 |
186.00 |
234.00 |
1,255.00 |
514.00 |
Per
Share (GAAP Quarterly, in $) |
(Dec 31 2019) IV. Quarter |
(Sep 30 2019) III. Quarter |
(Jun 30 2019) II. Quarter |
(Dec 31 2018) IV. Quarter |
(Sep 30 2018) III. Quarter |
Basic EPS (excl. extra
items) |
2.87 |
0.09 |
0.11 |
0.28 |
0.31 |
Extraordinary items |
0.00 |
0.00 |
0.00 |
0.00 |
0.00 |
Basic Net EPS |
2.87 |
0.09 |
0.11 |
0.28 |
0.31 |
Basic shares outstanding (Mill.
of Units) |
1,394.20 |
1,393.10 |
1,391.00 |
1,384.20 |
1,382.80 |
EPS other shares |
- |
- |
- |
- |
- |
Diluted Net EPS |
2.83 |
0.09 |
0.11 |
0.27 |
0.31 |
Diluted average shares (Mill.
of Units) |
1,413.20 |
1,412.20 |
1,408.60 |
1,406.00 |
1,403.90 |
Dividend per share |
- |
- |
- |
- |
- |
|
|